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Summary: A single nucleotide substitution and the effect on the phenotype in an Indonesian family with ß-
thalassaemia, HbE-trait and HbE-ß-thalassaemia is described. In the proposita (female, age 20 (Hb 7.4 mmol/1;
MCV 72 fl; MCH 1.45 fmol; HbA2 3.5%; HbF 2.4%)). an A/G mutation in the RNA cleavage and polyadenylation
sequence was detected (AATAAA/AATAGA). Her sister (Hb 8.2 mmol/1; MCV 77 fl; MCH 1.60 fmol; HbA2/HbE
32.4%), carried a different mutation in the ß-globin gene (codon 25; G129/A), and consequently had HbE-trait.
Their mother had a haemoglobin concentration of 6.4 mmol/1 (MCV 56 fl; MCH 1.20 fmol; HbA2/HbE 55.8%).
She was compound heterozygous for the mutation in the poly -signal and HbE-trait. Using restriction enzyme
analysis and linkage studies, we subsequently identified six family members with HbE-ß-thalassaemia, five with
ß-thalassaemia and six with HbE-trait. Two individuals were unaffected. The mutation in the polyadenylation
sequence causes a mild form of ß+-thalassaemia. The MCV and MCH in individuals with both ß-thalassaemia and
HbE-trait were significantly lower, yet on average they were only slightly more anaemic than those carrying only
the thalassaemic gene.
Introduction
ß-Thalassaemias constitute a heterogeneous group of
genetic disorders that result from a reduced ( "1") or
absent ( °) synthesis of ß-globin chains, due to aber-
rant ß-globin mKNA (1). Over 160 mutations causing
a ß-thalassaemia phenotype have been described; many
of these are characteristic for the population in which
they are observed (2). The disease has a considerable
phenotypic variation depending on many factors in-
cluding the nature of the mutation involved, co-inheri-
tance of other genetic factors influencing non-ß-globin
synthesis (3) and presence of the mutation in the
homo- or heterozygous state. Heterozygous patients
are clincally asymptomatic and may have a microcytic,
hypochromic anaemia, typically with elevated levels of
haemoglobin A2 (HbA2) (4). Biochemical presentation,
however, may also be normal or nearly normal, caus-
ing problems in diagnosis and hence in genetic coun-
selling (5).
The common haemoglobinopathy haemoglobin E
(HbE), is caused by a point mutation at codon 26 in the
ß-globin gene (G/A), resulting not only in a structural
haemoglobin variant but also affecting mRNA splicing
(6). The clinical phenotype is that of a mild form of ß-
thalassaemia (7). Consequently, inherited together with
ß-thalassaemia a marked deficit of ß-chain production
is to be expected, leading to a clinical picture of severe
ß-thalassaemia (8). In fact, HbE-ß-thalassaemia shows
an extraordinary variability in clinical expression. Pa-
tients may be either severely affected or have a rela-
tively mild clinical expression of the disease. This is due
to the kind of mutation and/or to genetic modifiers
linked to the globin gene clusters or located elsewhere
in the genome.
Routinely, ß-thalassaemia diagnosis is based on the de-
tection of an elevated HbA2 using electrophoretic or
Chromatographie techniques. These techniques are com-
mercially available and in general sufficient to correctly
diagnose these disorders. However, when HbA2 fraction
is normal and nevertheless there is suspicion of ß-thalas-
saemia, other techniques for carrier detection should be
used. HbE co-migrates with HbA2 in several electropho-
retic systems, making the detection of compound hetero-
zygotes for ß-thalassaemia/HbE-trait difficult by routine
analysis. In this study we used molecular biology tech-
niques to solve these problems. A better insight into the
clinical expression of specific mutations may be of im-
portance in predicting the degree of clinical severity and
influence the decisions concerning the prevention and
the therapy of these diseases. We therefore charac-
terized, on the molecular and biochemical level, a rare
mutation in the ß-globin gene in an Indonesian family
with ß-thalassaemia, HbE-trait and HbE-ß-thalassaemia.
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Materials and Methods
P a t i e n t s
Subjects under study were the proband and her family (her grand-
parents, their nine children and nine grandchildren; for age and
gender data see tabs. 1-3). Informed consent was obtained from
all subjects.
B i o c h e m i c a l and haemato log ica l assays
Haemoglobin concentration, red cell indices and erythrocytes were
measured using an automated cell counter (Sysmex Toa E-5000,
Toa Medical Electronics, Kobe, Japan). Reticulocyte count was
performed by flow cytometric analysis (Sysmex R-1000, Toa Med^·
ical Electronics, Kobe, Japan). Iron status was evaluated by meas-
uring serum ferritin (radioimmunoassay, Diagnostic Products Cor-
poration, Los Angeles, CA, USA), serum iron and serum transfer-
rin using a Hitachi 717 (Boehringer Mannheim, Germany). Haemo-
globin molecules were separated by gel electrophoresis at pH 8.5
using the Beckman Paragon System according to the instructions
of the manufacturer (Beckman Instruments, Brea? CA, USA). Elec-
trophoresis was carried out on 3 μΐ of haemolyzed washed red cells
for 25 minutes at 150 V. Dried gels were scanned at 595 nm. HPLC
was carried out using the MDMS-modular system (BioRad,
Veenendaal, The Netherlands), with an analytical cation exchange
column, according to the instructions of the manufacturer.
Isola t ion of genomic DNA
Blood for extraction of genomic DNA was collected in tubes con-
taining K3-EDTA at a final concentration of 3.9 mmol/1. The DNA
was isolated using a commercial DNA extraction kit (Stratagene;
cat. No. 200600χ according to the instructions of the manufacturer.
Polymerase chain reaction (PCR) of genomic DNA
Two specific fragments (designated 5* and 3') of the -globin gene
were amplified by the polymerase chain reaction using two oligo-
nucleotide primer sets: EC-1/2 and EC-3/4.
EC-1/2:
sense 5'-CCCTGTGGAGCCACACCCTA-3' and
antisense5'-ACGATCCTGAGACTTCCACAC-3'
amplify the 5f-fragment of 742 base pairs from nt-103, relative to
the cap site, to nt 144 of IVS-II.1)
EC-3/4:
sense 5'-TGCCTCTTTGCACCATTCTAAAG-3! and
antisense5'-TGCACTGACCTCCCACATTCC-3'
amplify the 3'-fragment of 571 base pairs from IVS-II nt 603 to nt
+ 194, relative to the termination codon. For detection of the codon
26 G/A mutation, we used a primer set to generate a 338 base pair
fragment, from nt -19 relative to the cap site, to codon 46 in the
second exon: EG1/2.
EG 1/2:
sense 5'-GCAGAGCCATCTATTGCTTAC-3' and
antisense5'-CCAAAGGACTCAAAGAACCTC-3'.
PCR was performed using the DNA thermal cycler 9600 (Perkin
Elmer (Norwalk, CT)) in 100 μΐ volumes containing 10 mmol/1
Tris-HCl, pH 8.3, 50 mmol/1 KC1, 1.5 mmol/1 MgCl2, 0.1 g/1 gela-
tine, 0.2 mmol/1 of each dNTP, 1 μηιοΐ/ΐ of each primer, - 5 μg
genomic DNA, and 2.5 U AmpliTaq DNA polymerase. All reagents
were obtained from Perkin Elmer. The samples were subjected to
30 cycles of amplification with denaturation at 94 °C for 1 minute
(5 minutes at 95 °C in the first cycle), annealing at 64 °C for 1
minute and extension at 72 °C for 1 minute followed by an elon-
gated extension time of 7 minutes after the last cycle. Negative
') Abbreviations:
MCV: mean corpuscular volume
MCH: mean corpuscular haemoglobin
RDW: red cell distribution width
IVS: intervening sequence
controls, without added DNA, were included in each run to exclude
amplification of contaminating DNA. Twenty μΐ of the amplified
PCR product was electrophorescd on a 30 g/1 agarose-gel and visu-
alized using ethidium bromide. The φΧ174 ΌΝΑΉαβΠΙ digest
from Promega was used as relative molecular mass marker.
The α-globin gene clusters were screened for deletions using PCR,
according to Bowden et al. (9) and Dodo et al. (10).
Restriction enzyme analysis
To demonstrate the presence of the codon 26 G/A mutation causing
HbE, 20 μΐ of the amplified fragment was digested with 20 U of
Hphl (New England Biolabs), according to the manufacturer's in-
structions, for 2 hours at 37 °C. Restriction fragments were electro-
phoresed and visualized as described above. Normal -globin PCR-
fragments contain two recognition sites for this restriction enzyme
(5'-GGTGA(N)8/-3'), while PCR-fragments with the codon 26 G/A
mutation have one such site. For detection of the polymorphisms
at codon 2 (C/T) and IVS-2; nt 16 (C/G), we digested 20 μΐ of the
5'-fragment with 20 U of s/HKAI and Avail (New England Bio-
labs) respectively, under the conditions as described for Hphl.
s/ΉΚΑΙ recognizes 5'-G[A,T]GC[A,T]/C-3' and Avail 5f-G/
G[A,T]CC-3'. Presence of homozygous T in codon 2 results in two
restriction fragments using s/ΗΚΑΙ, while homozygous C results
in three fragments. PCR-fragments homozygous for G at position
IVS-2; nt 16 are cleaved into two fragments using Avail and into
three fragments when homozygous for C.
Purif icat ion and nucleot ide sequencing of PCR-
amplif ied -globin DNA segments
Amplified genomic DNA segments were electrophoresed as de-
scribed under PCR of genomic DNA, and isolated from the gel
using the Prep-A-Gene DNA purification kit (BioRad). Single-
stranded DNA for nucleotide sequencing was prepared by asym-
metric PCR using the same reaction conditions as described for
PCR of genomic DNA except that in each reaction one of the two
primers was in excess (primer concentrations 0.5 μηιοΐ/ΐ and 0.01
μπιοΐ/ΐ, respectively); the template DNA used was 50 ng of isolated
double-stranded DNA and the concentration of each dNTP was
decreased to 0.05 mmol/1. To remove excess dNTP and to concen-
trate the single-stranded DNA in the asymmetric PCR product it
was filtered through Ultrafree MC 30.000 NMWL filter units
(Millipore, Bedford, MA, USA). Nucleotide sequencing was per-
formed using Sequenase, kit version 2.0 (US Biochemicals, Cleve-
land, OH, USA) and relevant oligonucleotides.
Results
Clinical and biochemical characterization
The results of the family investigations are presented in
tables 1-3. The proposita (tab. 1, family member 13) is
a Dutch female of Indonesian origin. At 20 years of age
she was admitted to the hospital for unexplained fatigue
and loss of weight. Repeated laboratory analysis of the
blood showed a normal to mildly decreased haemoglo-
bin (7.4 mmol/1; for reference values see tab. 1), slightly
microcytic (72 fl) and hypochromic red cells (MCH1)
1.45 fmol). Haemoglobin electrophoresis indicated a
marginally elevated HbA2 of 3.5% and haemoglobin F
of 2.4%. There was no iron deficiency (iron, ferritin,
transferrin and C-reactive protein within the reference
range) and no indication of haemolysis (bilirubin, hapto-
globin and reticulocytes all normal). Liver and spleen
were not enlarged.
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Her mother, a woman of Indonesian origin (tab. 3;
family member 4), had a concentration of 6.4 mmol/1,
with a markedly decreased MCV1) of 56 fl and MCH
of 1.20 finol. Haemoglobin electrophoresis indicated a
distinctly elevated fraction of HbA2/HbE (55.8%) and
an elevated fraction of HbF of 3.3%. Reticulocytes
(4.1%) and bilirubin (60 μηιοΙ/1) were elevated, hapto-
globin concentration was decreased (0.3 g/1). Liver
and spleen were not enlarged, as shown by ultrasound
techniques. During her two pregnancies the haemoglo-
bin concentration dropped to 4.5 mmol/1, but no
transfusions were given.
The only sister of the proposita (tab. 2; family member
12) had no anaemia (Hb 8.2 mmol/1), but marginally
decreased red cell indices (MCV 77 fl; MCH 1.60 fmol).
Haemoglobin electrophoresis showed a band of 32.4%
migrating in the HbA2 region and an HbF-band of 1.8%.
She was healthy and liver and spleen were not enlarged.
The father of the proposita was not available for exami-
nation.
On the basis of the clinical, haematological and bio-
chemical data, we concluded the presence of a haemo-
globinopathy in the sister of the proposita. Since the
haematological abnormalities were more pronounced in
the mother we postulated the presence of a second muta-
tion in (most likely) her -globin genes. We concluded
the proposita had a mild form of -thalassaemia, inher-
ited from her mother.
Tab. 1 Family members with -thalassaemia
Family member
Age (years)
Sex
Hb (mmol/1)
Erythrocytes (10I2/1)
MCV (fl)
MCH (fmol)
RDW(fl)
Reticulocytes (%)
HbA2 (%)
HbF (%)
Tab. 2 Family members
Family member
Age (years)
Sex
Hb (mmol/1)
Erythrocytes (1012/1)
MCV (fl)
MCH (fool)
ROW (fl)
Reticulocytes (%)
HbA2 ~H HbE (%)
HbF (%)
N.D.: not determined.
Tab. 3 Family members
Family member
Age (years)
Sex
Hb (mmol/1)
Erythrocytes (1012/1)
MCV (fl)
MCH (fool)
RDW(fl)
Reticujocytes (%)
HbA2 + HbE (%)
HbF (%)
1
62
7.7
4.96
78
1.55
24.9
1.2
4.4
1.2
with HbE
2
71
3
9.1
5.93
75
1.54
25.9
2.0
30.9
1.2
7
36
9
7.6
4.98
74
1.53
25.8
2.1
4.5
0.9
3
45
9.0
5.81
72
1.55
24.5
1.3
32.1
1.3
with -thalassaemia and
4
43
6.4
5.35
56
1.20
20.6
4.1
55.8
3.3
5
41
6.2
5.06
61
1.23
22.7
4.3
53.1
3.7
13*
20
7.4
5.10
72
1.45
22.5
2.0
3.5
2.4
11
31
3
9.4
N.D.
73
1.51
23.7
N.D.
29.6
N.D.
HbE
6
37
3
7.4
6.57
57
1.13
22.6
2.2
53.3
1.2
15
14
3
8.1
5.64
72
1.44
23.2
1.5
4.5
1.0
12
23
8.2
N.D.
77
1.60
25.1
1.7
32.4
1.8
8
35
δ
7.9
6.47
61
1.22
22.0
2.7
55.9
1.5
17
18
8.1
5.09
77
1.59
23.7
1.6
4.1
2.0
14
19
3
8.5
5.20
79
1.64
28.5
1.3
30.8
1.2
9
33
<ί
8.1
6.91
58
1.17
22.2
2.7
53.2
2.3
18
4
3
6.5
4.46
72
1.46
23.7
1.9
4.6
1.1
19
1
7.6
5.27
69
1.44
24.4
1.2
30.2
2.5
10
32
$
7.1
6.11
58
1.16
21.2
2.9
54.1
2.1
Reference values
9
7.8-10.0
4-5.5
80-102
1.8-2.2
23-36
0.4-2
<3.2
3
8.5-10.5
4.4-5.8
80-102
1.8-2.2
23-36
0.4-2
<3.2
Reference values
2
7.8-10.0
4-5.5
80-102
1.8-2.2
23-36
0.4-2
<3.2
3
8.5-10.5
4.4-5.8
80-102
1.8-2.2
23-36
0.4-2
<3.2
Reference values
?
7.8-10.0
4-5.5
80-102
1.8-2.2
23-36
0.4-2
<3.2
O
8.5-10.5
4.4-5.8
80-102
1.8-2.2
23-36
0.4-2
<3.2
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Gene a n a l y s i s
Fragments of the ß-globin gene of the proposita were
PCR-amplified using primers EC-1/2 and EC-3/4. Direct
sequencing revealed a mutation in the RNA cleavage
and polyadenylation sequence-(AATAAA/AATAGA).
No other mutations could be identified in the gene. In
addition, known ß-globin gene polymorphisms were de-
tected at codon 2 (C/C) and IVS-2; nt 16 (C/C). ß-Glo-
bin genes of the grandparents (family members 1 and 2)
were subsequently amplified and sequenced. The grand-
father (family member 2) was heterozygous for the
known codon 26 mutation causing haemoglobin E
(HbE). The ß-globin gene polymorphisms (vide supra)
were T/T (codon 2) and G/G (IVS-2; nt 16). In the ß-
globin gene of the grandmother (family member 1) the
same mutation as in the proposita was detected (AA-
TAAA/AATAGA). The ß-globin gene polymorphisms
were C/C (codon 2) and C/C (IVS-2; nt 16).
Since the electrophoretic and Chromatographie systems
used cannot separate HbA2 and HbE from each other, we
devised a strategy using elementary molecular biology
techniques in order to characterize the ß-globin genes of
other family members. The codon 26 mutation causing
haemoglobin E was detected by demonstration of the loss
of an Hphl restriction site. This mutation was present in
twelve family members (tabs. 2 and 3; family members
2-6, 8-12, 14 and 19). For the mutation in the RNA
cleavage and polyadenylation sequence (AATAAA/AA-
TAGA), no restriction enzyme is available to date. To
avoid extensive DNA-sequencing we aimed at demon-
strating linkage between the detected polymorphisms and
the mutations in the ß-globin genes. If this was so, we
could use restriction enzyme analysis to demonstrate the
presence of the AATAAA/AATAGA mutation. For se-
cond generation individuals this was not possible, since
they all were heterozygous for both polymorphisms. We
had to make one assumption, that judging from the bio-
chemical data, family members with unusually high HbE/
HbA2 fraction (tab. 3) would be compound heterozygotes,
since we knew from Hphl analysis they at least carried the
codon 26 mutation. To test this assumption we sequenced
the ß-globin gene fragments of family members numbers
4 (mother of the proposita), 5, 6, 8, and 9. They were
shown to carry both mutation in trans and were heterozy-
gous for both polymorphisms. The gene of family mem-
ber number 7 was also sequenced and only the AATAAA/
AATAGA mutation was detected. She was heterozygous
for both polymorphisms. By use of restriction enzyme
analysis it was shown that the codon 26 mutation causing
HbE was linked to a T in codon 2 (fig. 1) and a G at nucle-
otide 16 in IVS-2. The AATAAA/AATAGA mutation co-
segregated with a C in codon 2 (fig. 1) and a C at position
16 in IVS-2. We characterized the third generation of the
family on the molecular level using linkage of the mut-
ations to the gene polymorphisms.
Out of 20 family members we identified 6 with HbE-ß-
thalassaemia, 6 with ß-thalassaemia and 6 with HbE-
trait. Two individuals were unaffected (fig. 2). The bio-
chemical presentation of each group of patients was re-
markably homogeneous, except for the proposita with
only slightly elevated levels of HbA2 (tabs. 1—3). The
molecular diagnosis correlated with the diagnosis based
on the clinical and biochemical data.
No -globin gene deletions were detected in this family
as determined by PCR techniques..
 r
Discussion
Difficulty in diagnosing ß-thalassaemia in individuals
with borderline or only slightly elevated HbA2 levels is
not uncommon. The proposita described in this study
was only slightly anaemic, her MCV and MCH were
lowered and the fraction of HbA2 was marginally ele-
19 r
om
Base
pairs
489-
328-
253-
161-
M N
·**
CT CC CT CC CT CT CC TT CT
Fig. 1 Linkage of the ß-thalassaemia mutation (black area in ped-
igree) and the haemoglobin E mutation (hatched area in pedigree)
to the gene polymorphism in codon 2 (C/T), using restriction en-
zyme (AsiHKI) analysis. Numbers in pedigree corresponds to fam-
ily numbers. M: molecular size marker. N: normal heterozygous
control.
d>
Fig. 2 Pedigree of an Indonesian family showing all genetically
related individuals. Squares denote males, circles females. Hatched
area indicates heterozygote for haemoglobin E; black area indicates
heterozygote for ß-thalassaemia; white area symbolizes normal ß-
globin gene(s).
* indicates the proposita.
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vated. Consequently, the final diagnosis remained un-
certain. We chose to screen her mother and only sister
to detect any haematological abnormality, in order to
elucidate a possible genetic origin for the observed
properties. The results of this screening prompted us
to sequence the ß-globin gene of the proposita. The
detected mutation in the RNA cleavage and polyade-
nylation sequence (AATAAA/AATAGA) has been de-
scribed once before, but no haematological data were
presented for the heterozygous patient (11). As shown
here in six related individuals, the mutation causes a
mild form of ß^-thalassaemia. On average, haemoglo-
bin concentrations are in the lower part of the refer-
ence range. MCV and MCH values are decreased. All
patients except the proposita had clearly elevated
HbA2 concentrations.
We demonstrate here that linkage studies, using restric-
tion enzyme analysis, provide a useful method for the
molecular diagnosis of ß-thalassaemia in this family, al-
lowing simple detection of the disease even in neonatal
individuals. Similar approaches might be applicable for
a variety of other genetic diseases.
3'-End processing of newly formed RNA transcripts
consists of endonucleolytic cleavage of the primary tran-
script followed by polyadenylation of the upstream frag-
ment (12, 13). This cleavage is directed by several se-
quence elements in the RNA. The upstream AAUAAA
sequence is highly conserved and is located 10—30 nu-
cleotides upstream from the poly(A) addition site (12).
Many mutagenesis experiments and analysis of naturally
occuring mutations have shown that this hexanucleotide
is essential for proper cleavage. Six different mutations
in this element in the ß-globin gene have been described
to date, but their occurence is uncommon. Two deletions
(AATAAA/AAAA (14); AATAAA/A (15) and four
point mutations (AATAAA/AACAAA (16); AATAAA/
AATGAA and AATAAA/AATAGA (11); AATAAA/
AATAAG (17) have been published to date. The muta-
tion AATAAA/AATGAA was also described in a homo-
zygous condition (18). The mutations lead to ß+-thalas-
saemia and even the homozygous patient expressed a
mild form of ß-thalassaemia. Rund et al. have shown in
three patients in which the mutated AATAAG allele was
the only gene capable of producing RNA for ß-globin,
an expression of 12—34% of normally cleaved and poly^·
adenylated ß-globin mRNA (15). This indicated that this
particular type of mutation does not totally abolish
cleavage and polyadenylation. In addition, several
studies have shown the existence of multiple elongated
ß-globin mRNA's in patients carrying mutations in the
poly(A) signal, indicating the use of alternative down-
stream AATAAA sites (15, 16). It was suggested (16)
and concluded (15) that part of these transcripts were
translated, although inefficiently.
The effect on the mRNA level of the poly A mutation de-
scribed here has not been reported. As judged from the
phenotype of the six patients in our study, a similar effect
of this mutation on the expression of the gene might be
anticipated. However, comparison of our data with the
haematological data presented for the female patient het-
erozygous for the mutation AATAAA/AATGAA (18),
does show a milder phenotype associated with the latter
(Hb 8.7 mmol/1, MCV 83 fl, HbA2 3.7%). Three patients
heterozygous for AATAAA/AATGAA as described by
Jancovic et al. (11), express phenotypes comparable with
the patients described in the present study. This indicates
that phenotypic expression of a specific mutation is not
only dependent on the kind of mutation, but in addition
is influenced by a variety of other genetic factors (2, 19).
Studies on the RNA level are needed to confirm the hy-
pothesized molecular mechanisms explaining the relation
between this genotype and its effects.
Six other members of the family under investigation are
carriers of a G/A mutation in codon 26 and consequently
have HbE-trait. They have normal haemoglobin concen-
trations, but lowered MCV and MCH values. The muta-
tion results in the structurally abnormal haemoglobin E.
In addition, a cryptic splice site is created, leading to a
diminished production of ßE-globin, which explains the
clinical phenotype of a mild ß-thalassaemia (6, 20).
Consequently, when inherited together with ß-thalassae-
mia, a marked deficit of ß-chain production and a clin-
ical phenotype of severe ß-thalassaemia might be ex-
pected (8). In fact, the clinical expression of this disor-
der varies widely, due to e. g. co-inheritance of a-thalas-
saemia (19), kind of ß-globin gene mutations (21, 22)
and other genetic factors (2). The six patients in the pre-
sent study who had ß-thalassaemia/HbE-trait, expressed
a mild disease. Two patients with the lowest haemoglo-
bin concentrations had relatively high HbF levels and
reticulocyte counts. Possibly an additional genetic factor
located outside the sequenced segment of the ß-globin
gene or -globin genes is responsible for this phenome-
non. Additional studies are necessary to identify, if pre-
sent, such a factor. To our knowledge only one patient
has been described with identical mutations in the ß-
globin genes (11). Comparison of the haematological
data on the six members of the described family who
have ß-thalassaemia/HbE trait (tab. 3), with the data of
the previously published patient, illustrate the influence
of other genetic factors on the phenotype. This patient
had a haemoglobin of 5.9 mmol/1, significantly lower
than the male patients published here. MCV was similar
(59 fl), but his HbF fraction was clearly higher (7.6%).
Even considering the low MCV and MCH values, the
phenotypic expression of the combined disease in our
patients is surprisingly mild. Although we have not iden-
tified ameliorating factors, the presence of such modifi-
ers in the described family is feasible.
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